Biosimilar Insights

31. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

32. A Custom Path To The Clinic: Inside A Collaborative Model 6/19/2026

    Balancing speed, compliance, and control is no small task. A different approach to external support is emerging—one that prioritizes knowledge transfer, collaboration, and long-term confidence.

33. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

34. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

35. Simplifying ADC Development Through CDMO Collaboration 6/17/2026

    Two CDMOs are working together to simplify ADC development. Learn how integrated support and collaboration can reduce complexity, streamline transfers, and keep programs moving forward.

36. Collaborative Supply Chain Management In A Fragmented World 6/15/2026

    Biopharma supply chains are under pressure. As regionalization accelerates, success depends on agility, trust, and new approaches to collaboration that can withstand ongoing global uncertainty.

37. Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs) 6/15/2026

    ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.

38. ADC Manufacturing: Practices, Challenges, And The Road Ahead 6/15/2026

    ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.

39. Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors 6/15/2026

    Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.

40. Evaluating Antibody Fragment Purification Using VH3 Resin 5/22/2026

    Explore how VH-domain targeting enables efficient purification of VH3 antibody fragments and bispecific formats, with strong recoveries and flexible wash conditions that support improved purity.